Connor, Clark & Lunn Investment Management Ltd. Citius Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 10, 2022	SELL	$1.51 - $2.2 $260,834 - $380,023	-172,738 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.74 - $2.6 $300,564 - $449,118	172,738 New	172,738 $351,000

Others Institutions Holding CTXR

# of Institutions

Shares Held

30.6M

Call Options Held

24.7K

Put Options Held

Armistice Capital, LLC New York, NY

10.2M
Shares

$4.37 Million
0.08% of portfolio
Vanguard Group Inc Valley Forge, PA

6.33M
Shares

$2.72 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.05M
Shares

$881,009
0.0% of portfolio
Black Rock Inc. New York, NY

1.81M
Shares

$776,462
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.65M
Shares

$707,907
0.0% of portfolio

View Full List

About Citius Pharmaceuticals, Inc.

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $62.8M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

More about CTXR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account